7380 COCA COLA DRIVE, HANOVER, MD
Dr. Sian Bigora Transitions to Part-Time Role at Processa Pharmaceuticals
End of Material Contract
Processa Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price
1-for-25 Reverse Stock Split Approved for Processa Pharmaceuticals
Amended material disclosure
News
Shareholder votes
Q1
Amended Annual Report
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(4)
Effectiveness Notice
S-1
Direct Registration System
Definitive Proxy Statement
Additional Proxy Materials
PRER14A
PRE 14A
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence